Abstract 108P
Background
Triple negative breast cancer (TNBC) is defined as hormone receptors less than 1% and human epithelial growth factor receptor 2 (HER2) negative by immunofluorescence. HER2 negative tumors can express an intracellular domain and present a HER2 positive phenotype. Before Trastuzumab era, the prognostic was worse in HER2 over expressed early breast cancer than in triple negative counterpart.
Methods
We conducted a retrospective analysis in order to explore the clinical significance of different degrees of tumor HER2 immunohistochemistry expression: 0, 1 or 2 inside triple breast cancer population.
Results
We analysed data from 440 early stage breast cancer patients, primary treated by surgery, addressed to the Department of Medical Oncology of University Hospital of Lille France, for adjuvant chemotherapy, between January 2010 and April 2013. 47 patients (10, 6%) had triple negative phenotype, 67pts (15,2%) HER2 positive, 326 pts (74, 1%) luminal. The mean age was 47 years, 19 %( 9pts) and deleterious BRCA1 or BRCA2 mutations were found in 10 pts (21%). The patients were more likely to have stage IIA 48 %( 23pts), invasive ductal carcinoma 74 %( 35pts), the surgery was conservatory in 28 pts(59,5pts)and the majority, 44pts (93%) was anthracycline exposed. The distribution of HER2 score among TN patients were as follows: 62% (29pts) negative, 27,6 %( 13pts) one plus, 10,4 %( 5pts) two plus and negative for in situ hybridization. HER 2 positivity correlated with pT (p = 0, 05), Ki67 (p = 0, 06) and tumor grade (p = 0, 08). Pathologic stage pT, Ki67, and HER2 score were associated with relapse (p
Conclusions
The proportion of HER2 positivity inside TNBC population is valuable. The HER2 score 2 correlates with prognostic negative tumor features and associates with poor outcome in our analysis.
Clinical trial identification
Legal entity responsible for the study
University Hospital of Lille France
Funding
University Hospital of Lille France
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract